12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zytiga abiraterone acetate: Interim Phase III data

Johnson & Johnson unblinded the double-blind, international Phase III COU-AA-302 trial at the recommendation of an independent DMC after a planned interim analysis showed that Zytiga plus prednisone showed "evidence of clinical benefit" on the co-primary endpoints of radiographic PFS and OS, as well as secondary endpoints, vs. placebo plus prednisone. Details of...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >